FDA commissioner not a star witness
Executive Summary
The "accuracy and candor" of statements by FDA Commissioner Andrew von Eschenbach at recent House Energy and Commerce/Oversight and Investigations Subcommittee hearings concerning approval of Sanofi Aventis's Ketek are being scrutinized by the panel. In a letter to HHS Secretary Michael Leavitt, full committee chairman John Dingell, D-Mich., and subcommittee head Bart Stupak, D-Mich., request all briefing materials and communications related to von Eschenbach's remarks, as well as interviews with agency staff who helped prepare the testimony. The records were due by April 4, but the committee said it had not received an "adequate response"...
|
The "accuracy and candor" of statements by FDA Commissioner Andrew von Eschenbach at recent House Energy and Commerce/Oversight and Investigations Subcommittee hearings concerning approval of Sanofi Aventis's Ketek are being scrutinized by the panel. In a letter to HHS Secretary Michael Leavitt, full committee chairman John Dingell, D-Mich., and subcommittee head Bart Stupak, D-Mich., request all briefing materials and communications related to von Eschenbach's remarks, as well as interviews with agency staff who helped prepare the testimony. The records were due by April 4, but the committee said it had not received an "adequate response".... |